NCT01479764View on ClinicalTrials.gov

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

PHASE3CompletedINTERVENTIONAL

Enrollment

154

Participants

Timeline

Start Date

December 2, 2011

Primary Completion Date

October 26, 2012

Study Completion Date

November 5, 2012

Conditions

Surgical Procedures, Elective

Interventions

DRUG

Sugammadex

sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery

DRUG

Neostigmine

neostigmine, per usual practice

DRUG

Glycopyrrolate

glycopyrrolate per usual practice

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01479764 - Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) | Biotech Hunter | Biotech Hunter